Advances in Cardiovascular Risk Reduction

Friday, May 20, 2016


NYU Langone Medical Center
550 First Avenue 
Alumni Hall, Farkas Auditorium 
New York, NY 10016

Course Brochure

Register Online*

Register Via Fax*

*After 12 pm on May 18, 2016, only onsite registration is available, provided the course has not reached capacity. Onsite registrants will incur an additional $20 fee. Registration is non-transferable.

Course Director

Arthur Schwartzbard, MD

Course Fees

Full Fee: $175
Reduced Fee*: $60
NYU Langone Faculty and Staff: $60
NYU Langone Residents & Fellows: Waived (must provide valid NYU Langone ID)
Outside Residents and Fellows: $25

*Reduced fee applies to NYU School of Medicine alumni, former residents and fellows; physician-in-training; physicians employed by the Department of Veterans Affairs Medical Center; full-time active military personnel; nurse practitioners; retired physicians; and all other non-physician healthcare professionals.

This course is being offered in conjunction with the Dietary Strategies for Cardiovascular Risk Reduction course on Thursday, May 19, 2016. We are offering a steep Diet course registration discount to participants who register for both events. Click here to view the brochure and register online for Dietary Strategies in Cardiovascular Risk Reduction Course.

Target Audience

Internists, family practitioners, cardiologists, general practice, endocrinologists and nurse practitioners with an interest in the prevention of heart disease.  Lecture, case conference and a Q&A panel discussion give learners multiple methods of instruction to interact with the information being presented

Course Description

This one-day course will cover state-of-the-art management of patients with cardiovascular risk factors, with a focus on prevention. This year’s program focuses on recent clinical trial results with implications in the management of cardiovascular disease risk factors, such as diabetes, hypertension and ischemia. Additional topics include new developments in PCSK9 treatments for familial hypercholesterolemia, the use of aspirin in cardiac prevention and weight loss surgery insights. The course will also explore how environmental toxins can affect cardiovascular health.
Each year this course includes a research-oriented presentation that highlights bench-to-bedside relevance. This year the featured research-oriented presentation will focus on the latest in insulin resistance in type 2 diabetes.
Eight (8) half-hour presentations will be given. During lunch, attendees will participate in a case conference with challenging cases in cardiovascular disease risk reduction. Course participants are given the opportunity to submit questions to the featured speakers and panel members. The course will include a morning and afternoon panel discussion segment in which the questions from the audience are answered and debated among panel members.


Statement of Need

  • A recent study, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) demonstrated that glucose-lowering with a sodium-glucose cotransporter (SGLT2), resulted in a lower rate of morbidity and mortality from cardiovascular causes. This is the first time any glucose-lowering agent has shown to improve cardiovascular outcomes.  This study has the potential to change standard of care.  
  • Basic science researchers have made significant strides in understanding and treating Type 2 Diabetes in animal models.  Recently, researchers have developed an agent that can reverse type 2 diabetes in rats.  This research shows great promise for translational medicine, paving the way for further studies and possible clinical trials that may benefit humans.  Additional scientific research elucidates the pathogenesis of the metabolic syndrome, a risk factor for cardiovascular disease and insulin resistance in type 2 diabetes. Dr. Shulman’s laboratory has been at the forefront of defining the causes of insulin resistance in type 2 diabetes. He and his colleagues are developing novel therapies to treat non-alcoholic liver diseases and its associated defect in insulin suppression of gluconeogenesis.
  • A recent study, Systolic Blood Pressure Intervention Trial, known as SPRINT, showed significant benefit to lowering blood pressure well below current guidelines.  This major study concluded early due to the lifesaving reduction in morbidity and mortality in patients who were assigned to achieve a systolic blood pressure lower than 120.   These significant results will likely lead to changes in clinical practice and national blood pressure guidelines.
  • In 2015, the FDA approved the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.  New studies shed light on this new avenue of treatment.  
  • Ischemic heart disease (IHD) affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. It is not known if invasive approaches are better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease. The ISCHEMIA trial is designed to answer that question.
  • Since the discovery that low-dose aspirin can reduce the risk of heart attack, anti-platelet agents have become an increasingly important tool for preventing cardiovascular events. While aspirin is the most widely used and best studied anti-platelet agent, newer agents are also available. This activity will review current concepts and options in anti-platelet therapy.
  • Obesity now exceeds 34% of US adults.  Recent studies have examined the effects of bariatric surgery on glycemic control.  For severely obese patients, bariatric surgery may be the optimal method of achieving glucose control.  Studies have also shown that bariatric surgery results in long-term weight loss, improved lifestyle, and positive outcomes on cardiovascular disease risk factors. 
  • Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and mounting evidence indicates that toxicant exposures can profoundly impact on CVD risk. Epidemiologic studies have suggested that arsenic exposure is positively related to increases in blood pressure, a primary risk factor for cardiovascular disease. Additionally, epidemiological studies have demonstrated an increased risk of cardiovascular disease with exposure to ambient air pollution. 

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Discuss the EMPA-REG Outcome trial results and the potential impact on diabetes treatment approaches
  • Discuss recent scientific advances in the understanding of diabetes and related disorders
  • Describe the rationale behind the design of the SPRINT trial
  • Describe how, PCSK9 modulates LDL levels and how PCSK9 expression is affected by statin treatment
  • Describe the rationale behind the ISCHEMIA trial and how this trial may affect standard of care in patients with stable ischemic heart disease 
  • Summarize the role of aspirin in preventing cardiovascular events and their efficacy and safety in light of recent clinical trials
  • Describe surgical interventions for obesity and the effects on co-morbidities such as cardiovascular disease and diabetes
  • Describe the role of toxins, such as air pollution, as a risk for cardiovascular disease

Accreditation Statement

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The NYU Post-Graduate Medical School designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ​

Refund Policy

In order to request a refund, you must email no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund. 

Course Cancellation Policy

If a course is cancelled due to inclement weather, insufficient enrollment, or any other reason, NYU PGMS will refund registration fees in full. NYU PGMS will provide at least two weeks’ advance notice if cancelling due to insufficient enrollment and as soon as possible in all other circumstances. NYU PGMS is not responsible for any airfare, hotel, or other non-cancellable costs incurred by the registrant.